Federal Circuit Mandamus- Petitioners Target PTAB’s Discretionary

If patent law had a mood board lately, it would feature one exhausted in-house counsel, one very determined PTAB petitioner, and a giant sign flashing: “Discretion means discretion.” That is the heart of the current fight over discretionary denials at the Patent Trial and Appeal Board. Petitioners have been trying to convince the U.S. Court of Appeals for the Federal Circuit to step in through mandamus and curb the U.S. Patent and Trademark Office’s increasingly assertive control over whether inter partes review, or IPR, gets instituted at all. So far, the court’s response has been about as warm as a tax audit.

The legal and strategic battle has become one of the most important stories in modern PTAB practice. It matters because IPR was designed as a faster, specialized way to test patent validity, especially when the same patent is being asserted in district court. But over the past year, the rules of engagement have shifted. The USPTO has separated discretionary review from merits review, expanded the menu of factors that can support denial, and reinforced the Director’s central role in institution decisions. Petitioners, unhappy with the new terrain, have fired off a wave of mandamus petitions. The Federal Circuit has answered with a steady series of denials.

Why This Fight Matters So Much

For companies sued on patents, an IPR petition is often more than a procedural filing. It is a strategic counterpunch. District court litigation can be expensive, broad, and painfully slow until it suddenly is not. By contrast, PTAB review can be technical, streamlined, and focused on printed prior art. For years, accused infringers saw IPR as a powerful way to challenge patent claims while also pressuring the broader litigation.

That is why discretionary denial hits so hard. When the PTAB declines to institute even though the petition may be serious on the merits, the petitioner loses a preferred forum. In many cases, the denial also reshapes settlement leverage, litigation timing, expert budgeting, and the overall defense playbook. In plain English: a denied IPR does not just sting; it can change the entire war map.

The tension is not new. PTAB discretionary denial has long been controversial, especially under the NHK-Fintiv line of decisions, which let the agency consider parallel district court litigation when deciding whether to institute review. Critics say that approach can reward fast-moving patent suits and make PTAB access feel unpredictable. Supporters say it prevents duplicative proceedings and protects agency resources. Either way, the debate has now moved from policy arguments to a direct appellate campaign.

What Petitioners Are Actually Targeting

A Newer, More Structured Discretionary Framework

The modern wave of challenges took off after the USPTO’s March 26, 2025 memorandum on PTAB workload management. That memo did not merely tweak formatting or deadline trivia. It changed the institution process in a meaningful way by bifurcating review. Discretionary considerations would be handled separately from merits and other non-discretionary issues. Patent owners could file a dedicated brief asking for discretionary denial, and the Director would resolve those discretionary issues before the case moved forward in the normal course.

That shift mattered because it made discretionary denial more formal, more visible, and, in many cases, more central. The new framework also highlighted a broader set of considerations, including familiar themes like parallel litigation and serial petitions, but also more policy-sensitive ideas such as “settled expectations.” That phrase sounds harmless enough, like something from a couples therapist or a very polite accounting firm. In practice, though, it can be a serious obstacle for petitioners, especially where the patent has been in force for years and the agency concludes that disturbing the status quo is not worth the institutional cost.

The Retreat From Petitioner-Friendly Assumptions

Petitioners also reacted strongly to the rollback of earlier guidance that many had viewed as more favorable to institution. Under former Director guidance, a Sotera-style stipulation could significantly reduce overlap concerns in parallel district court litigation. That did not create a guaranteed safe harbor, but petitioners often treated it as a major institution-friendly move. By 2025, however, the USPTO had made clear that such stipulations were no longer automatically decisive. Helpful? Yes. Magical? Not anymore.

At the same time, the agency started emphasizing issues like serial attacks, copycat petitions, timing, patent age, overlap with other proceedings, and the practical value of using PTAB resources in a given case. The message was unmistakable: institution is not a customer loyalty program. Filing fees get you consideration, not a boarding pass.

Why Mandamus Looked Like an Attractive Weapon

Here is the procedural snag. Institution decisions are famously shielded from ordinary appellate review. Congress gave the Director broad discretion over whether to institute IPR, and the statute says those determinations are “final and nonappealable.” That has made direct review extraordinarily difficult. So petitioners looking for a way around that barrier reached for mandamus, an extraordinary writ reserved for extraordinary situations.

Mandamus can be appealing in theory when a party believes an agency has acted outside the law, ignored constitutional protections, or changed policy in a legally defective way. The petitioners’ arguments have varied, but they generally cluster around a few themes. Some say the USPTO effectively changed the rules without proper notice-and-comment rulemaking. Others argue the agency acted arbitrarily, relied on improper factors, violated due process, or exceeded its statutory authority. A few petitions have tried to package those arguments as separation-of-powers or retroactivity problems.

That strategy was clever. It was also, at least so far, unsuccessful.

The Federal Circuit’s Answer: Mostly “No, and Also No”

The First Big Set of Denials

The turning point came with the Federal Circuit’s November and December 2025 decisions, especially In re Motorola Solutions and the related orders that followed. In Motorola, the court rejected a petition seeking to undo PTAB deinstitution decisions tied to the changed discretionary regime. The petitioner argued that the Acting Director’s shift in guidance violated the Administrative Procedure Act and the Due Process Clause. The Federal Circuit refused to grant mandamus relief.

That decision quickly became the anchor for later denials. Petitioners in cases involving Google, Samsung, Cambridge, HighLevel, and SanDisk made variations of the same larger complaint: the PTAB had moved the goalposts, and the court should make the agency put them back. The Federal Circuit remained unmoved. Its reasoning was consistent: institution decisions are largely insulated from review, mandamus is not a shortcut around that bar, and many APA-style complaints belong in a separate district court action if they are reviewable at all.

The 2026 Wave That Confirmed the Trend

If anyone thought those first denials were isolated or fact-specific, early 2026 removed the suspense. The Federal Circuit denied another string of mandamus petitions in cases involving Intel, Kangxi, Tessell, Kahoot!, Tesla, Google, and Volkswagen. The factual settings varied. Some challenges focused on “settled expectations.” Others attacked the use of parallel litigation, reexamination efficiency, or policy-based resource management. Still others tried to cast the USPTO’s conduct as ultra vires or constitutionally suspect.

The results were basically identical. The court treated these petitions as attempts to relitigate institution discretion through a procedural side door. That door, the court made clear, remains heavily locked.

The emerging pattern is now hard to miss. Petitioners are not merely losing one-off disputes; they are confronting a broader judicial stance that discretionary denials are, in most circumstances, not for the Federal Circuit to second-guess through mandamus.

The Legal Logic Behind the Court’s Resistance

Institution Is Discretionary by Design

The Federal Circuit’s core reasoning rests on the structure of the America Invents Act and prior precedent. Congress gave the Director discretion over whether to institute IPR. That means meeting threshold statutory conditions does not create an entitlement to review. A petitioner may deserve serious consideration, but it does not have a legal right to institution.

That point matters because mandamus requires a “clear and indisputable” right to relief. When the underlying statute says the agency has discretion and the institution decision is nonappealable, the petitioner begins the race halfway underwater.

Due Process Arguments Have Not Gained Traction

Several petitioners argued that they relied on prior USPTO guidance and were unfairly disadvantaged when the agency changed course. The Federal Circuit has largely treated those reliance arguments as insufficient to create a protected property interest. In other words, expecting the agency to keep using a favorable discretionary framework is not the same thing as possessing a vested legal right.

That is a painful distinction for petitioners, but it is a doctrinally important one. The court has signaled that disappointment, even expensive disappointment, does not automatically become a due process violation.

APA Challenges May Survive, but Usually Somewhere Else

One of the more important nuances in this area comes from Apple v. Vidal and the later 2026 decision in Apple v. Squires. Those cases help explain that some Administrative Procedure Act challenges to PTAB-related policy can exist separately from a direct attack on a specific institution decision. But that does not mean mandamus is the right tool.

Indeed, the Federal Circuit has repeatedly suggested that broad procedural APA claims belong, if anywhere, in district court rather than in a writ asking the appellate court to effectively force institution in an individual PTAB matter. That distinction may sound technical, but it is hugely practical. It means the fight is not necessarily over. It just may need to happen on a different battlefield, with a different vehicle, on a slower timetable. Patent litigators love that. Said no one ever.

What This Means for PTAB Strategy Going Forward

The immediate lesson is simple: petitioners should stop treating mandamus as a realistic reset button for discretionary denial. The Federal Circuit has now built a substantial body of recent decisions showing that most such petitions will fail unless they present something truly exceptional.

That does not mean petitioners are out of options. It means they need better option planning.

First, timing has become even more important. If parallel district court litigation is likely to loom large, petitioners must think earlier and act earlier. Waiting too long and then asking the PTAB to rescue the schedule is no longer a convincing strategy.

Second, petitioners need to build the discretionary record with as much care as the merits record. That includes explaining why institution would be an efficient use of agency resources, why overlap is manageable, why any stipulation meaningfully narrows duplication, and why the patent owner’s “settled expectations” argument is weak on the facts.

Third, companies may need to diversify invalidity strategy. As practitioners have increasingly noted, ex parte reexamination is drawing more attention as an alternative path for some challengers. It lacks the same procedural profile and strategic advantages as IPR, but in a world where discretionary denials have grown more prominent, parties will naturally look for other ways to put prior art before the agency.

Fourth, broader APA litigation remains relevant. If industry players want to attack the legality of the USPTO’s discretionary-denial framework itself, rather than simply reverse a single denial, district court challenges may remain the more plausible route. That path is longer, messier, and less satisfying than an emergency writ. It is also, at this point, the one the Federal Circuit keeps pointing toward.

Why Patent Owners Are Watching With Popcorn

Patent owners have plenty of reasons to like the current trend. A stronger discretionary screen can reduce duplicative battles, preserve litigation momentum, and protect older patents from late-breaking administrative attacks. It can also reward a patent owner that has already invested heavily in district court or won favorable rulings elsewhere.

Of course, patent owners should not get too comfortable. The legal and political debate over PTAB access is not finished. Rulemaking, legislation, more APA suits, and future changes in USPTO leadership could reshape the landscape again. In patent law, the only truly permanent thing is that someone, somewhere, is drafting a petition about it.

Experience From the Real World: What This Feels Like for the People Living It

In practice, the fight over PTAB discretionary denials feels less like an abstract administrative law seminar and more like controlled turbulence in a crowded cabin. For many litigation teams, the old rhythm was familiar. A complaint lands. The defendant evaluates prior art, files IPR petitions, considers a stay motion, and models settlement leverage around the possibility that the PTAB may institute review. That rhythm has now become much less predictable.

One common experience is internal whiplash. Business leaders hear, “We have strong prior art,” and naturally assume that means the PTAB will take the case. Then outside counsel has to explain that strong prior art may still lose the institution race if the district court case is too far along, if the patent is considered old enough to support “settled expectations,” or if the agency decides the matter is not a good use of resources. That conversation is rarely fun. It is especially not fun after the filing fees have already gone out the door.

Another recurring experience is strategy compression. Petitioners now have to think about discretionary denial much earlier and much more explicitly. Teams cannot treat it as a side issue buried in a footnote near the back of the binder. They must ask hard questions right away: Should we file earlier? Can we narrow overlap with a stronger stipulation? Do we need to coordinate district court positions more carefully? Would ex parte reexamination make more sense for this patent? The margin for casual sequencing has shrunk.

Patent owners, meanwhile, often describe a very different emotional arc. For them, the newer framework can feel like long-awaited recognition that PTAB review is not supposed to be a reflexive second front in every infringement case. A patent owner that has spent years building a portfolio, litigating a case, surviving claim construction, and investing heavily in trial preparation may view discretionary denial as simple fairness. To that party, “settled expectations” is not just a slogan; it is a real-world argument about stability, cost, and reliance.

There is also a practical experience shared by both sides: more briefing, more forecasting, and more client education. Lawyers now spend extra time explaining not just whether a petition is likely to win on the merits, but whether the agency is likely to even reach the merits. Clients want numbers. Lawyers want caveats. Everyone wants certainty. Nobody gets enough of it.

Perhaps the biggest experience, though, is cultural. PTAB practice used to feel, at least to many petitioners, like a largely technical exercise with a relatively defined set of gatekeeping rules. Today it feels more openly policy-inflected. Resource allocation, litigation posture, patent age, and institutional concerns now sit closer to center stage. That shift changes how cases are planned, how budgets are approved, and how risk is communicated inside companies.

And that may be the most honest takeaway of all: the battle over discretionary denial is not just about mandamus petitions or one line in the U.S. Code. It is about who gets meaningful access to one of the most important patent validity forums in the country, on what terms, and with how much predictability. Until that question settles down, PTAB practice will keep feeling a little like chess played on a moving walkway.

Conclusion

The current Federal Circuit trend sends a strong signal. Petitioners may dislike the PTAB’s evolving discretionary-denial regime, but mandamus has not become the magic key for reopening institution decisions. The court has repeatedly emphasized the Director’s broad discretion, the statutory limits on review, and the narrow role of extraordinary writs in this setting.

That does not end the debate over whether the USPTO’s newer framework is wise, fair, or durable. It simply clarifies one important point: if challengers want to reshape the rules, they likely need to do more than ask the Federal Circuit to rescue a denied petition. They may need to win through district court APA litigation, future rulemaking fights, smarter filing strategies, or eventual legislative reform.

For now, though, the message from the appellate bench is straightforward. PTAB discretion remains alive, well, and impressively difficult to lasso.